Last reviewed · How we verify

NCT03153748: NATIONAL-2

New Therapeutic System of Ruptured Intracranial Aneurysms Based on Big Data From Chinese Population

Status unknown Last updated 15 May 2017
What this trial tests

trial in Subarachnoid Hemorrhage, Aneurysmal in 10,000 participants. Status unknown.

Timeline
1 July 2016
Primary endpoint
31 December 2020
31 December 2020

Quick facts

Lead sponsorChanghai Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment10,000
Start date1 July 2016
Primary completion31 December 2020
Estimated completion31 December 2020
Sites1 location across China

Conditions studied

Sponsor

Changhai Hospital

Who can join

Eligibility, any sex, with Subarachnoid Hemorrhage, Aneurysmal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims at clarifying the current situation of Emergency treatment of aneurysmal subarachnoid hemorrhage (SAH) in China, and analyzing the safety and efficacy of the treatment strategy between interventional treatment and open surgery, so as to improve the diagnosis and treatment of aneurysmal SAH.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Subarachnoid Hemorrhage, Aneurysmal

Currently open trials in the same condition.

Other Changhai Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03153748.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing